Navigation Links
MiMedx Group, Inc. Adds Ronald G. Wallace to Board of Directors
Date:5/1/2008

TAMPA, Fla., May 1 /PRNewswire-FirstCall/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG) announced today that Ronald G. Wallace, former President of UPS International, has been appointed to its Board of Directors, effective April 29, 2008.

Commenting on the appointment, Thomas D'Alonzo, Chief Executive Officer, stated "We are delighted to bring someone of Ron's stature, independence and knowledge to our Board. Ron's financial acumen and his experience with running a large international business will provide great value to the Company as he works with the Board and its Audit and Compensation Committees to assist us in the implementation of our vision and strategy."

Mr. Wallace is the former President of UPS International and member of the Management Committee that is responsible for the day to day operations of the company. UPS is a 90 billion dollar company with over 400,000 employees worldwide. Mr. Wallace's responsibilities included the development of UPS in over 220 countries. He joined UPS in 1966 and held key management positions throughout his career. Mr. Wallace served on 34 different UPS boards throughout the world and was a member of the World Trade Center. He presently is a director on several boards, including the National Board for Speedway Childrens Charity. He served as Chairman for the Georgia Governor's Commission and was responsible for the development of the new City of Milton. Mr. Wallace is also a Lieutenant, in charge of the reserve unit for the Alpharetta Police Department, and was awarded the Directors Award last year.

About MiMedx Group, Inc.

MiMedx Group, Inc. is the parent company for MiMedx, Inc., a development-stage Florida corporation founded in 2006, with technology focusing on biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as other biomaterial-based products for other medical applications. MiMedx, Inc., based in Tampa, Florida, holds an exclusive, worldwide license from the Shriner's Hospital for Children and the University of South Florida Research Foundation for certain nordihydroguaiaretic acid (NDGA) technology. MiMedx is targeting this proprietary technology for a number of diverse medical applications.

MiMedx, Inc. also has a wholly-owned subsidiary, SpineMedica, LLC, based in Atlanta, Georgia, led by an industry veteran, R. Lewis Bennett. SpineMedica, a Florida limited liability company, is a development-stage company focusing on the commercialization of medical device technologies for application in the spine and chronic back pain. SpineMedica's goal is to acquire promising technologies in this field through licensing arrangements and develop and commercialize such technologies.

For further information, please refer to the Current Report on Form 8-K to be filed by MiMedx Group, Inc. with the SEC as soon as practicable, which will be accessible at: http://www.sec.gov/cgi-bin/browse- edgar?action=getcompany&CIK=0001376339&owner=include&count=40l. You may also contact Matthew J. Miller, Executive Vice President of MiMedx Group, at 813-866-0000, for additional information.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Post-split Name Change
2. MiMedx Announces Brian J. Splan as President
3. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
4. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
5. Photonic Products Group, Inc. Reports Record Financial Results for FY 2007
6. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
7. The Ensign Group, Inc. Declares Quarterly Dividend of $0.04 Per Share
8. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
9. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System ... standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
Breaking Biology Technology:
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):